Aline de Fátima Bonetti

Aline de Fátima Bonetti

Auto-generated profile, based on publicly available information

Aline de Fátima Bonetti

Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, PR, Brasil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
CMCamilla R. Madeira
Camilla R. Madeira
FTFernanda Tonin
Fernanda Tonin
MFMariana Millan Fachi
Mariana Millan Fachi
HBHelena H. Borba
Helena H. Borba
VFVinicius L. Ferreira
Vinicius L. Ferreira
RPRoberto Pontarolo
Roberto Pontarolo

16 July 2018 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
RLRosa C. Lucchetta
Rosa C. Lucchetta
FTFernanda Tonin
Fernanda Tonin
HBHelena H. L. Borba
Helena H. L. Borba
LLLetícia Leonart
Letícia Leonart
VFVinicius L. Ferreira
Vinicius L. Ferreira
AWAstrid Wiens
Astrid Wiens

31 December 2017 in Pharmacy Practice
Verified
Journal Article
Open access
WRWálleri C. Reis
Wálleri C. Reis
ABAline F. Bonetti
Aline F. Bonetti
WBWallace E. Bottacin
Wallace E. Bottacin
ARAlcindo S. Reis
Alcindo S. Reis
TSThaís T. Souza
Thaís T. Souza
FFFernando Fernandez-Llimos
Fernando Fernandez-Llimos
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

24 April 2018 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
PDF file
ABAline F. Bonetti
Aline F. Bonetti
WRWálleri C. Reis
Wálleri C. Reis
NLNatália Fracaro Lombardi
Natália Fracaro Lombardi
AMAntonio Eduardo Matoso Mendes
Antonio Eduardo Matoso Mendes
HNHarli Pasquini Netto
Harli Pasquini Netto
RPRoberto Pontarolo
Roberto Pontarolo

16 June 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
MFMariana Millan Fachi
Mariana Millan Fachi
LBLays de Deus Bueno
Lays de Deus Bueno
DODenise Colaço Oliveira
Denise Colaço Oliveira
LSLetícia Lazarin Silva
Letícia Lazarin Silva
ABAline F. Bonetti
Aline F. Bonetti
What is known and objective Hyperprolactinemia is a neuroendocrine disease that is responsible for a quarter of cases of secondary amenorrhea, which can lead to infertility in women. Dopaminergic agonists (bromocriptine, cabergoline, quinagolide) can be used in the treatment. However, there is a lack of secondary studies that compare their efficacy and safety, especially through a network meta-analysis. Thus, to contribute to the decision-making, a systematic review and network meta-analyses (NMA) were performed to evaluate the efficacy and safety of dopaminergic agonists in the treatment of hyperprolactinemia. Methods Randomized clinical trials (RCT) were retrieved through PubMed, Web of Science and Scopus databases. The efficacy and safety of the drugs were compared, considering the following outcomes: prolactin (PRL) levels, number of patients with galactorrhoea, menstrual irregularities and adverse drug reactions. NMA was built for each outcome. Results were reported as odds ratios (OR) with 95% credibility intervals. Ranking probabilities were calculated by surface under the cumulative ranking analysis (SUCRA) and Stochastic multicriteria acceptability analysis (SMAA). Results and discussion Seventeen RCTs were included in the systematic review and fifteen in the meta-analyses. The drugs had similar efficacy, considering the PRL levels. The SUCRA analysis showed that quinagolide (0.075 and 0.05 mg/day) was superior for reducing irregular menstruation, whereas bromocriptine was the best (97%) for galactorrhoea. Cabergoline proved to be the safest drug, except for abdominal pain at a dose of 1 mg/week. The SMAA demonstrated similar results to SUCRA. What is new and conclusion This is the first network meta-analysis that evaluated the efficacy and safety of dopaminergic agonists in the treatment of hyperprolactinemia. The results of this review revealed that these drugs have similar efficacy, but cabergoline has a better safety profile.

1 February 2022 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
ABAline F. Bonetti
Aline F. Bonetti
FTFernanda Tonin
Fernanda Tonin
RLRosa C. Lucchetta
Rosa C. Lucchetta
RPRoberto Pontarolo
Roberto Pontarolo
FFFernando Fernandez-Llimos
Fernando Fernandez-Llimos